Replies to post #682401 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

SRD is 10.9% at risk at five years. For DCVax-l
MRD is 10.6% at risk at five years for DCVax-l

Long term survival is where the impact is expected to be highest with cancer vaccine therapy.

You’ll also notice it appears significant residual disease (where I logically assume most mesenchymal are) will surpass minimum residual disease by year six.

This would not be the case with SOC therapy. It would be the opposite, and by a much wider margin.